DL-肾上腺素盐酸盐 | 52134-32-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 中文名称: DL-肾上腺素盐酸盐
• 中文别名: (+-)-4-〔1-羟基-2-(甲基氨基)乙基〕-1,2-苯二醇盐酸盐；(+/-)-肾上腺素盐酸盐
• 英文名称: Racepinefrine hydrochloride, (S)-
• 英文别名: 4-[(1S)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol;hydrochloride
• CAS: 52134-32-4
• 化学式: C9H14ClNO3
• 分子量: 219.66
• InChiKey: ATADHKWKHYVBTJ-SBSPUUFOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.77
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  72.7
• 氢给体数：
  5
• 氢受体数：
  4

文献信息

• Anti-glycation agents for preventing age- diabetes- and smoking-related complications
  申请人：Yeboah Faustinus

  公开号：US20050043408A1

  公开（公告）日：2005-02-24

  The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.

  这项发明提供了新的蛋白质糖基化抑制剂，通过高通量筛选检测从化合物库中鉴定出来。所鉴定的抗糖基化剂具有多种化学结构，可用于预防或治疗与年龄、糖尿病和吸烟有关的并发症，包括神经病变、肾病、眼部病理或胶原组织的机械性能丧失。在被鉴定为具有抗糖基化活性的化合物中，特别感兴趣的是肾上腺素及其类似物，特别是D-肾上腺素及其类似物，可用于预防或治疗与年龄、糖尿病和吸烟有关的眼部病理。
• ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS
  申请人：YEBOAH Faustinus

  公开号：US20080139664A1

  公开（公告）日：2008-06-12

  The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.

  该发明提供了新的蛋白质糖基化抑制剂，通过高通量筛选检测从化合物库中确定。所确定的抗糖基化剂具有各种化学结构，并可用于预防或治疗与年龄、糖尿病和吸烟相关的并发症，包括神经病变、肾病、眼部病理或胶原组织机械性能的丧失。在被确定为具有抗糖基化活性的化合物中，特别感兴趣的是肾上腺素及其类似物，特别是D-肾上腺素及其类似物，这些物质特别适用于预防或治疗与年龄、糖尿病和吸烟相关的眼部病理。
• [EN] ANTI-GLYCATION AGENTS FOR PREVENTING AGE-, DIABETES-, AND SMOKING-RELATED COMPLICATIONS<br/>[FR] AGENTS ANTI-GLYCATION DESTINES A LA PREVENTION DES COMPLICATIONS LIEES A L'AGE, AU DIABETE ET AU TABAGISME
  申请人：CA NAT RESEARCH COUNCIL

  公开号：WO2003032969A2

  公开（公告）日：2003-04-24

  The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.